vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and INVESTORS TITLE CO (ITIC). Click either name above to swap in a different company.
INVESTORS TITLE CO is the larger business by last-quarter revenue ($69.5M vs $62.1M, roughly 1.1× Cytek Biosciences, Inc.). On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -1.6%). INVESTORS TITLE CO produced more free cash flow last quarter ($25.4M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 14.0%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
CTKB vs ITIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $69.5M |
| Net Profit | $-44.1M | — |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 13.8% |
| Net Margin | -70.9% | — |
| Revenue YoY | 8.1% | -1.6% |
| Net Profit YoY | -557.1% | — |
| EPS (diluted) | — | $3.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $69.5M | ||
| Q3 25 | $52.3M | $73.0M | ||
| Q2 25 | $45.6M | $73.6M | ||
| Q1 25 | $41.5M | $56.6M | ||
| Q4 24 | $57.5M | $70.6M | ||
| Q3 24 | $51.5M | $68.8M | ||
| Q2 24 | $46.6M | $65.4M | ||
| Q1 24 | $44.9M | $53.5M |
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | $12.2M | ||
| Q2 25 | $-5.6M | $12.3M | ||
| Q1 25 | $-11.4M | $3.2M | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $941.0K | $9.3M | ||
| Q2 24 | $-10.4M | $8.9M | ||
| Q1 24 | $-6.2M | $4.5M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 13.8% | ||
| Q3 25 | -17.6% | 20.7% | ||
| Q2 25 | -23.3% | 21.5% | ||
| Q1 25 | -36.1% | 7.2% | ||
| Q4 24 | 5.2% | 15.3% | ||
| Q3 24 | -8.2% | 16.8% | ||
| Q2 24 | -18.3% | 17.2% | ||
| Q1 24 | -23.9% | 10.8% |
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | 16.7% | ||
| Q2 25 | -12.2% | 16.7% | ||
| Q1 25 | -27.5% | 5.6% | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 1.8% | 13.5% | ||
| Q2 24 | -22.4% | 13.6% | ||
| Q1 24 | -13.8% | 8.5% |
| Q4 25 | — | $3.97 | ||
| Q3 25 | — | $6.45 | ||
| Q2 25 | — | $6.48 | ||
| Q1 25 | — | $1.67 | ||
| Q4 24 | — | $4.41 | ||
| Q3 24 | — | $4.92 | ||
| Q2 24 | — | $4.70 | ||
| Q1 24 | — | $2.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $89.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $268.3M |
| Total Assets | $461.5M | $363.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $89.6M | ||
| Q3 25 | $93.3M | $110.8M | ||
| Q2 25 | $75.5M | $90.1M | ||
| Q1 25 | $95.3M | $81.7M | ||
| Q4 24 | $98.7M | $83.8M | ||
| Q3 24 | $162.3M | $112.9M | ||
| Q2 24 | $177.9M | $111.2M | ||
| Q1 24 | $168.8M | $135.0M |
| Q4 25 | $341.7M | $268.3M | ||
| Q3 25 | $378.6M | $278.0M | ||
| Q2 25 | $377.6M | $266.2M | ||
| Q1 25 | $379.6M | $254.4M | ||
| Q4 24 | $395.7M | $251.8M | ||
| Q3 24 | $385.5M | $271.3M | ||
| Q2 24 | $389.1M | $261.8M | ||
| Q1 24 | $392.6M | $254.0M |
| Q4 25 | $461.5M | $363.1M | ||
| Q3 25 | $494.9M | $363.3M | ||
| Q2 25 | $493.3M | $345.8M | ||
| Q1 25 | $482.6M | $333.8M | ||
| Q4 24 | $499.5M | $333.6M | ||
| Q3 24 | $491.2M | $352.0M | ||
| Q2 24 | $483.7M | $340.3M | ||
| Q1 24 | $492.1M | $329.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $30.9M |
| Free Cash FlowOCF − Capex | $-1.8M | $25.4M |
| FCF MarginFCF / Revenue | -2.9% | 36.5% |
| Capex IntensityCapex / Revenue | 1.6% | 8.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $47.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $30.9M | ||
| Q3 25 | $-3.9M | $17.2M | ||
| Q2 25 | $108.0K | $8.9M | ||
| Q1 25 | $-125.0K | $-75.0K | ||
| Q4 24 | $2.0M | $29.8M | ||
| Q3 24 | $13.2M | $7.8M | ||
| Q2 24 | $6.2M | $8.4M | ||
| Q1 24 | $4.0M | $1.4M |
| Q4 25 | $-1.8M | $25.4M | ||
| Q3 25 | $-4.6M | $15.8M | ||
| Q2 25 | $-1.5M | $7.3M | ||
| Q1 25 | $-974.0K | $-1.4M | ||
| Q4 24 | $1.1M | $22.4M | ||
| Q3 24 | $12.2M | $6.1M | ||
| Q2 24 | $5.2M | $6.3M | ||
| Q1 24 | $3.4M | $-793.0K |
| Q4 25 | -2.9% | 36.5% | ||
| Q3 25 | -8.7% | 21.7% | ||
| Q2 25 | -3.2% | 9.9% | ||
| Q1 25 | -2.3% | -2.5% | ||
| Q4 24 | 1.9% | 31.7% | ||
| Q3 24 | 23.7% | 8.8% | ||
| Q2 24 | 11.0% | 9.7% | ||
| Q1 24 | 7.6% | -1.5% |
| Q4 25 | 1.6% | 8.0% | ||
| Q3 25 | 1.3% | 1.8% | ||
| Q2 25 | 3.5% | 2.1% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 1.6% | 10.5% | ||
| Q3 24 | 2.0% | 2.5% | ||
| Q2 24 | 2.3% | 3.2% | ||
| Q1 24 | 1.3% | 4.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | -0.02× | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | 0.84× | ||
| Q2 24 | — | 0.95× | ||
| Q1 24 | — | 0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
ITIC
Segment breakdown not available.
